How have VVOS shares performed in 2024?

Vivos Therapeutics' stock was trading at $12.44 at the beginning of the year. Since then, VVOS stock has decreased by 78.1% and is now trading at $2.72. View the best growth stocks for 2024 here .

Are investors shorting Vivos Therapeutics?

Vivos Therapeutics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 18,700 shares, a decrease of 28.6% from the March 15th total of 26,200 shares. Based on an average trading volume of 208,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.8% of the shares of the company are sold short. View Vivos Therapeutics' Short Interest .

When is Vivos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024. View our VVOS earnings forecast .

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its earnings results on Thursday, March, 28th. The company reported ($3.05) earnings per share for the quarter. The firm earned $3.25 million during the quarter. Vivos Therapeutics had a negative net margin of 98.42% and a negative trailing twelve-month return on equity of 665.17%.

When did Vivos Therapeutics' stock split?

Vivos Therapeutics's stock reverse split before market open on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Vivos Therapeutics IPO?

Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VVOS

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free VVOS Stock Alerts

$2.72

+0.06 (+2.26%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.61
▼
$2.74
50-Day Range: $2.64
▼
$5.81
52-Week Range: $2.40
▼
$48.79

Volume: 40,317 shs
Average Volume: 194,144 shs
Market Capitalization: $7.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Vivos Therapeutics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

VVOS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VVOS Stock News Headlines

April 15, 2024 | americanbankingnews.com

TELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis

April 12, 2024 | americanbankingnews.com

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Drop in Short Interest

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 11, 2024 | proactiveinvestors.com

Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval

April 9, 2024 | finance.yahoo.com

Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices

April 9, 2024 | markets.businessinsider.com

Vivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral Devices

April 9, 2024 | msn.com

What's Going On With Vivos Therapeutics Stock?

April 9, 2024 | msn.com

Medicare to reimburse for Vivos CARE sleep apnea devices

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 9, 2024 | proactiveinvestors.com

Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursement

April 9, 2024 | investorplace.com

Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?

April 9, 2024 | msn.com

Vivos Therapeutics files to sell 1.73M shares of common stock for holders

April 9, 2024 | finance.yahoo.com

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

April 9, 2024 | globenewswire.com

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

April 1, 2024 | proactiveinvestors.com

Vivos Therapeutics highlights path to cash flow positivity after FDA clearance

March 31, 2024 | finance.yahoo.com

Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations

March 30, 2024 | seekingalpha.com

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

March 29, 2024 | marketwatch.com

Vivos Therapeutics Shares Fall After Wider-Than-Expected 4Q Loss

March 28, 2024 | globenewswire.com

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

March 28, 2024 | globenewswire.com

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

February 22, 2024 | benzinga.com

Vivos Therapeutics Stock (NASDAQ:VVOS), Short Interest Report

February 22, 2024 | benzinga.com

Vivos Therapeutics Stock (NASDAQ:VVOS) Insider Trades

February 18, 2024 | investing.com

Vivos Therapeutics secures $4 million through warrant exercise

February 15, 2024 | finance.yahoo.com

Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds

February 15, 2024 | proactiveinvestors.com

Vivos Therapeutics sees gross proceeds of $4M from exercise of warrant

February 12, 2024 | finance.yahoo.com

Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions

February 6, 2024 | finanznachrichten.de

Vivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

See More Headlines

Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 6/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:VVOS
CUSIP: N/A
CIK: 1716166
Web: www.vivoslife.com
Phone: 866-908-4867
Fax: N/A
Employees: 154
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($11.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,580,000.00
Net Margins: -98.42%
Pretax Margin: -98.42%
Return on Equity: -665.17%
Return on Assets: -122.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.34
Quick Ratio: 0.34

Sales & Book Value

Annual Sales: $13.80 million
Price / Sales: 0.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.22 per share
Price / Book: 12.36

Miscellaneous

Outstanding Shares: 2,730,000
Free Float: 2,469,000
Market Cap: $7.43 million
Optionable: Optionable
Beta: 7.94

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. R. Kirk Huntsman (Age 66)
Co-Founder, Chairman of the Board & CEO
Comp: $482.16k
Mr. Bradford K. Amman (Age 62)
CFO, Treasurer & Secretary
Comp: $335.53k
Mr. Todd Huntsman
Co-Founder & Senior VP of Product and Technology
Ms. RaeAnn Byrnes
Co-Founder and Senior VP of Events & Clinical Advisory Services
Ms. Susan McCullough
Co-Founder & Executive VP of Operations
Ms. Julie Gannon
Senior VP of Strategic Sales & Marketing and Investor Relations Officer
Mr. Nicholas M. DeGennaro
Senior Vice President of Medical Integration Division
Ms. Ruth Hembree
Senior Vice President of Practice Services
Ms. Stephanie Huebner
Senior Vice President of Dental Service Integration
Mr. John Ballard
Senior Vice President of Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VVOS Stock Analysis - Frequently Asked Questions

How have VVOS shares performed in 2024?: Vivos Therapeutics' stock was trading at $12.44 at the beginning of the year. Since then, VVOS stock has decreased by 78.1% and is now trading at $2.72.
View the best growth stocks for 2024 here.
Are investors shorting Vivos Therapeutics?: Vivos Therapeutics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 18,700 shares, a decrease of 28.6% from the March 15th total of 26,200 shares. Based on an average trading volume of 208,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.8% of the shares of the company are sold short.
View Vivos Therapeutics' Short Interest.
When is Vivos Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024.
View our VVOS earnings forecast.
How were Vivos Therapeutics' earnings last quarter?: Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its earnings results on Thursday, March, 28th. The company reported ($3.05) earnings per share for the quarter. The firm earned $3.25 million during the quarter. Vivos Therapeutics had a negative net margin of 98.42% and a negative trailing twelve-month return on equity of 665.17%.

When did Vivos Therapeutics' stock split?: Vivos Therapeutics's stock reverse split before market open on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
When did Vivos Therapeutics IPO?: Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.
How do I buy shares of Vivos Therapeutics?: Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VVOS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

About Vivos Therapeutics Stock (NASDAQ:VVOS)

VVOS Stock Price History

VVOS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VVOS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info